Navigation Links
Sinovac Receives Drug Registration Certificate from Hong Kong Department of Health for Seasonal Flu Vaccine Anflu(R)
Date:10/24/2010

BEIJING, Oct 24 /PRNewswire-Asia-FirstCall/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac Biotech (Hong Kong) Ltd., its wholly owned subsidiary company in Hong Kong, has received the Certificate of Drug/Product Registration from the Hong Kong Department of Health for its seasonal influenza vaccine Anflu®. Sinovac filed the application with the Hong Kong Department of Health for the drug registration certificate for Anflu in November 2009. Obtaining the drug certificate in Hong Kong is a continuation of Sinovac's strategy to pursue opportunities to export its vaccines manufactured in mainland China to targeted areas and countries around the globe.

Dr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, "We are advancing our international sales strategy by obtaining regulatory approvals in targeted areas and countries that will enable us generate sales by exporting our commercialized vaccines. We have successfully registered Anflu in Hong Kong and are actively evaluating marketing and distribution opportunities in this market."

About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received the orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011.

Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.For further information, please contact:Helen YangSinovac Biotech Ltd.Tel:  +86-10-8279-9871Fax:  +86-10-6296-6910Email: info@sinovac.comInvestors:Stephanie Carrington/Amy GlynnThe Ruth GroupTel:  +1-646-536-7017/7023Email: scarrington@theruthgroup.comaglynn@theruthgroup.comMediaJason RandoThe Ruth GroupTel:  +1-646-536-7025Email: jrando@theruthgroup.com
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac to Host Conference Call to Report Second Quarter 2010 Financial Results
2. Sinovac Holds 2010 Annual Meeting of Shareholders
3. Sinovac Schedules 2010 Annual Meeting of Shareholders
4. Sinovac Selected by Beijing CDC to Supply Hepatitis A Vaccine Healive(R)
5. Sinovac Announces Plan to Launch Offering of Common Shares
6. Sinovac Announces Recent Developments
7. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
8. Sinovac Named One of Chinas Top 10 Most Competitive Companies Listed Overseas in 2009
9. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
10. Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government
11. Sinovac Files Shelf Registration Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute Ischemic Stroke Market and ... their offering.       (Logo: ... Acute Ischemic Stroke Market and Competitive Landscape ... Ischemic Stroke pipeline products, Acute Ischemic Stroke ...
(Date:5/4/2016)... 2016 Research and ... Acute lymphocytic Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
Breaking Medicine Technology:
(Date:5/4/2016)... , ... May 04, 2016 , ... ... developers and operators of commercial real estate proudly announced that its service-based charitable ... initiative. Team members portfolio-wide will continue Olshan Properties’ annual philanthropic tradition in ...
(Date:5/4/2016)... LA (PRWEB) , ... May 04, 2016 , ... Hight-Doland ... LA area has teamed up with Big Brothers Big Sisters of Southwest Louisiana to ... being accepted here . , Big Brothers Big Sisters of Southwest Louisiana has ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Dr. Elyson and ... tooth removal surgery at their office. Wisdom tooth removal, a common dental procedure, is ... problematic, they often are improperly erupted, resulting in risks of complications. By providing wisdom ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Natalie Jill ... with local company MitoXcell in preparation of the launch of her new book: Natalie ... plan is a nutritional guide designed to jump start a new healthy lifestyle featuring ...
(Date:5/4/2016)... ... May 04, 2016 , ... AudioEducator ... and compliance. In upcoming months, AudioEducator has lined up some informative training session ... designed to give complete compliance know-how and practical, easy-to-apply advice. , On Thursday, ...
Breaking Medicine News(10 mins):